Agenus (AGEN) Net Income towards Common Stockholders (2010 - 2026)
Agenus (AGEN) posted quarterly Net Income towards Common Stockholders of $39.2 million for Q1 2026, up 254.71% year-over-year from $11.0 million in Q1 2025, and up 468.43% quarter-over-quarter from -$10.6 million in Q4 2025.
Analysis
Agenus (AGEN) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Agenus' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $39.2 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 254.71% year-over-year to $39.2 million; the TTM figure through Mar 2026 stood at $64.4 million (up 133.75% YoY), while the FY2025 annual figure was -$101000.0, up 99.96% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at $39.2 million, up from -$10.6 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $63.9 million in Q3 2025, with the low at -$71.1 million in Q4 2022.
- The 5-year median for Net Income towards Common Stockholders is -$48.4 million (2022), against an average of -$38.5 million.
- The sharpest annual moves came in 2022 and 2026: Net Income towards Common Stockholders slumped 130.41% in 2022, then surged 254.71% in 2026.
- Agenus' Net Income towards Common Stockholders stood at -$71.1 million in 2022, then jumped by 34.86% to -$46.3 million in 2023, then climbed by 0.93% to -$45.9 million in 2024, then jumped by 76.84% to -$10.6 million in 2025, then surged by 468.43% to $39.2 million in 2026.
- Business Quant data shows AGEN's Net Income towards Common Stockholders at $39.2 million in Q1 2026, -$10.6 million in Q4 2025, and $63.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Agenus | 339.80 Mn | 339.80 Mn | 34.52 Mn | -604,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -604,000.00 |
| Mar 31, 2026 | 39.17 Mn |
| Dec 31, 2025 | -10.63 Mn |
| Sep 30, 2025 | 63.86 Mn |
| Jun 30, 2025 | -28.01 Mn |
| Mar 31, 2025 | -25.32 Mn |
| Dec 31, 2024 | -45.91 Mn |
| Sep 30, 2024 | -66.44 Mn |
| Jun 30, 2024 | -53.14 Mn |
| Mar 31, 2024 | -61.94 Mn |
| Dec 31, 2023 | -46.34 Mn |
| Sep 30, 2023 | -62.25 Mn |
| Jun 30, 2023 | -69.07 Mn |
| Mar 31, 2023 | -68.31 Mn |
| Dec 31, 2022 | -71.15 Mn |
| Sep 30, 2022 | -54.28 Mn |
| Jun 30, 2022 | -46.49 Mn |
| Mar 31, 2022 | -48.38 Mn |
| Dec 31, 2021 | -65.56 Mn |
| Sep 30, 2021 | 178.50 Mn |